Bemnifosbuvir-Ruzasvir (BEM/RZR) + Sofosbuvir-Velpatasvir (SOF/VEL)

Phase 3Active

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

HEPATITIS C VIRUS CHRONIC INFECTION

Conditions

HEPATITIS C VIRUS CHRONIC INFECTION

Trial Timeline

Apr 7, 2025 → Dec 1, 2026

NCT ID

NCT06868264

About Bemnifosbuvir-Ruzasvir (BEM/RZR) + Sofosbuvir-Velpatasvir (SOF/VEL)

Bemnifosbuvir-Ruzasvir (BEM/RZR) + Sofosbuvir-Velpatasvir (SOF/VEL) is a phase 3 stage product being developed by Atea Pharmaceuticals for HEPATITIS C VIRUS CHRONIC INFECTION. The current trial status is active. This product is registered under clinical trial identifier NCT06868264. Target conditions include HEPATITIS C VIRUS CHRONIC INFECTION.

What happened to similar drugs?

20 of 20 similar drugs in HEPATITIS C VIRUS CHRONIC INFECTION were approved

Approved (20) Terminated (8) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Pegylated Interferon + RibavirinAstellas PharmaApproved

✅Glecaprevir-pibrentasvirAbbVieApproved

✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved

✅PTV/r/OBV/DSVAbbVieApproved

✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved

✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06868264	Phase 3	Active	Apr 7, 2025	Dec 1, 2026	HEPATITIS C VIRUS CHRONIC INFECTION

Competing Products

20 competing products in HEPATITIS C VIRUS CHRONIC INFECTION

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
IVA337 + IVA337 + Placebo	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
Pegasys® + Pegasys®	Chugai Pharmaceutical	Approved	43
peginterferon alfa-2a + rivavirin	Chugai Pharmaceutical	Phase 3	40
SOF + COPE	Chugai Pharmaceutical	Pre-clinical	26
Colesevelam Hcl	Daiichi Sankyo	Phase 2	35
ASP9831 + Placebo	Astellas Pharma	Phase 2	35
FK788	Astellas Pharma	Phase 2	35
MK-2248	Merck	Phase 1	29
Interferon alfacon-1	Astellas Pharma	Phase 3	40
Pegylated Interferon + Ribavirin	Astellas Pharma	Approved	35
Tacrolimus + steroids, monoclonal anti-IL2R antibody	Astellas Pharma	Phase 2	35
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	29
Dolutegravir + Methadone	Shionogi	Phase 1	29
Clevudine + Adefovir	Eisai	Phase 3	40